Identification and Treatment of the Liability to Develop Schizophrenia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Central South University
• Collaborator: Ortho-McNeil Janssen Scientific Affairs, LLC
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Having at least one first-degree biological relative with schizophrenia and their age is between 19 and 59.

• Desire to participate in a medication trial.

• Is able to provide informed consent.

• Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS).

• Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, long-term verbal memory, and executive functions.

• Scoring at least one standard deviation below normal in a second cognitive domain.

Exclusion Criteria:

• IQ less than 80.

• Formal education less than 10 years.

• History of psychotic disorders.

• History of treatment with an antipsychotic medication.

• A substance abuse diagnosis within 6 months of diagnosis.

• A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits).

• A history of neurologic disease or damage.

• A medical condition with significant cognitive sequelae.

• A history of electroconvulsive treatment.